Tag Archives: regn

Regeneron Q1 Earnings Beat As Eylea Research Pays Off

Big-cap biotech Regeneron Pharmaceuticals (REGN) beat Wall Street’s Q1 estimates and raised its guidance Thursday, sending the stock up more than 2% in early trading. Regeneron’s earnings rose 27% over the year-earlier quarter to $2.88 a share, beating analysts’ consensus by 20 cents, according to Thomson Reuters. Revenue climbed 39% to $869.6 million, about $45 million above consensus. The beat came from U.S. sales of Regeneron’s flagship eye

Biotechs On Track For Worst Week In A Year

Biotechs are getting hit hard on the stock market today. The group has been the No. 1 group out of IBD’s 197 industries, but it’s on track for its worst weekly decline in about a year. Some top-rated biotech stocks taking a beating include Celgene (CELG), Biogen (BIIB) and Regeneron (REGN). Watch this video for IBD chart analysis of each stock. Follow Alissa Williams on Twitter: @IBD_AWilliams.

Investors Relieved? Akorn Stock Retakes 50-Day Line

Akorn (AKRX) shares made big gains in the stock market today. The drugmaker had to restate its Q2 and Q3 2014 financial statements because of an error that led to an overstatement of revenue and earnings in Q2. But investors seem to be relieved by the move. Watch this video for a breakdown of this highly rated stock’s chart action. Other drug stocks that moved on big news this week include Regeneron (REGN), Amgen (AMGN), Sanofi (SNY), Esperion